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Abstract: The data presented in this article are related to the research article entitled as ”Targeted
deletion of the BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising
approach for gene therapy of beta-thalassemia disease ” [1]. BCL11A is a master regulator of ￿-globin
gene silencing, and suppresses fetal hemoglobin expression by association with other ￿-globin suppressors,
and also interacts with human beta-globin locus control region as well as intergenic region between the
A￿ and ￿-globin genes to reconfigure beta-globin cluster. Thus, HbF reactivation has been proposed to be
an approach for the treatment of ￿-thalassemia through knockout of BCL11A. Accordingly, an erythroid
enhancer sequence was identified that, when inactivated, led to repression of BCL11A and induction
of ￿-globin in the erythroid lineage [2-7]. This article describes data that obtained from BCL11A gene
enhancer modification in KU812 and KG-1 cell lines using the CRISPR-Cas9 genome editing system in
order to reactivate ￿-globin gene expression.
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CRISPR-Cas9 genome editing system
a b s t r a c t
The data presented in this article are related to the research article
entitled as “Targeted deletion of the BCL11A gene by CRISPR-Cas9
system for fetal hemoglobin reactivation: A promising approach
for gene therapy of beta-thalassemia disease " [1]. BCL11A is a
master regulator of g-globin gene silencing, and suppresses fetal
hemoglobin expression by association with other g-globin sup-
pressors, and also interacts with human beta-globin locus control
region as well as intergenic region between the Ag and d-globin
genes to reconﬁgure beta-globin cluster. Thus, HbF reactivation has
been proposed to be an approach for the treatment of b-thalas-
semia through knockout of BCL11A. Accordingly, an erythroid
enhancer sequence was identiﬁed that, when inactivated, led to
repression of BCL11A and induction of g-globin in the erythroid
lineage [2e7]. This article describes data that obtained from
BCL11A gene enhancer modiﬁcation in KU812 and KG-1 cell lines
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using the CRISPR-Cas9 genome editing system in order to reac-
tivate g-globin gene expression.
© 2019 Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Data
This article shows targeted inactivation of BCL11A gene expression for induction of g-globin in the
erythroid lineage [2e7] using the CRISPR-Cas9 genome editing system through deletion of a 200 bp
sequence encompassing the GATA1motif within the BCL11A erythroid enhancer. Two sgRNAs based on
SaCas9 (ga) and four sgRNA based on SpCas9 (g) were designed using an online CRISPR design tool
(http://crispor.tefor.net/) (Fig. 1).
Cutting efﬁciency of each gRNA was determined by T7EI assay and Sanger sequencing in HEK293T
cells. Cutting efﬁciencies of 16%, 5%, and 12% obtained for guide RNAs gB, gC, and gD, respectively.
However, no cutting efﬁciency was determined for gRNAs gaI and gaII. Moreover, no cutting activity
was observed for gA by T7EI assay, but it showed activity when the target site was analyzed by Sanger
sequencing (Figs. 2 and 3-Add sequencing ﬁles Figs. 2 and 3 gaI, gaII, gA, gB, gC, gD, WT, and T7EI assay
data for Figs. 2 and 3). The constructs were subsequently transfected into KU812 and KG-1 cells.
Following validation of targeted genomic deletion by pairs of sgRNA using PCR (Fig. 4), quantitative
real-time PCR (qPCR) was performed on mRNAs puriﬁed from bulk cells, as well as on edited clones to
assess the mRNA level of BCL11A and g-globin (Fig. 5-Add qPCR data for Fig. 5).
Speciﬁcations Table
Subject area Biochemistry, Genetics and Molecular Biology
More speciﬁc subject area Biotechnology, Genome editing, Genetics, and Molecular Medicine
Type of data Graph, ﬁgure
How data was acquired Data were collected using PCR, Real-Time qPCR (QuantStudio™ 7) Flex Real-Time PCR
Systems (Applied Biosystems) and StepOne Plus Real-Time PCR Systems (Applied
Biosystems), Sanger sequencing, and GraphPad Prism 6
Data format Raw and analyzed
Experimental factors BCL11A and g-globin gene expression level were compared between wildtype
conditions and conditions after erythroid-speciﬁc BCL11A enhancer gene editing
through the CRISPR-Cas9 system in KU812 and KG-1 cells.
Experimental features BCL11A-knockout KU812 and KG-1 cell lines were established using the CRISPR-Cas9
genome editing system. Single-cell cloning was performed by serial dilution, and then
the expression level of BCL11A and g-globin were analyzed in clones.
Data source location Institute of Laboratory Animal Sciences - Institut für Labortierkunde (LTK)
Data accessibility The data are available for this article
Related research article M.A. Khosravi, M. Abbasalipour, J.-P. Concordet, J. Vom Berg, S. Zeinali, A. Arashkia, K.
Azadmanesh, T. Buch, M. Karimipoor, Targeted deletion of BCL11A gene by CRISPR-Cas9
system for fetal hemoglobin reactivation: A promising approach for gene therapy of
beta-thalassemia disease, Eur. J. Pharmacol. 854 (2019) 398e405. https://doi.org/10.
1016/J.EJPHAR.2019.04.042 [1].
Value of the Data
 These data provide information on the comparison of SaCa9 and SpCas9 in genome editing experiments.
 Provided data can be suitable to a comparative analysis between T7EI assay and Sanger sequencing, as methods for
analyzing of cutting efﬁciency.
 The dataset can be used to identify an appropriate cell line as a model for g-globin reactivation experiments.
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2. Experimental design, materials and methods
2.1. Designing and cloning of sgRNAs
Single-guide RNAs were designed using the online CRISPR design tool (http://crispor.tefor.net/)
[11,12]. Oligonucleotides encoding the sgRNAs were annealed and cloned into the BsmBI-digested
pMLM363, VVT1, and pMAK vectors as previously described [1].
2.2. Cell culture and transfection
HEK293T cell line was cultured in Dulbecco's minimal essential medium (high glucose) (DMEM,
Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Sigma). The KU812 cell line
Fig. 2. Evaluation of SpCas9 cutting efﬁciency in HEK293T cells. (A) The mutation frequency of sgRNAs was evaluated using T7
endonuclease I assay in HEK293T cells transfected with the pMLM3636-gA, pMLM3636-gB, pMLM3636-gC, pMLM3636-gD, and hCas9
expression vector. Primers ﬂanking the sgRNA recognition sequences were used to amplify regions around each sgRNA site, and the
ampliﬁed products were cleaved by the T7 endonuclease enzyme. Expression vectors with sgRNA were indicated as (þ), and control
vectors without sgRNAwere indicated as (). The efﬁciency of cleavage has been indicated as % indels below each gel. (B) The mutation
rate of sgRNA-Awas assessed by (B. I) T7EI assay, and (B. II) Sanger sequencing on bulk cells. The reference sequence has been shown at
the top, and the sequence derived from sgRNA-A transfected HEK293T cells has been shown below. NC: negative control.
Fig. 1. Schematic representation of single guide RNA (sgRNA) locations. Two sgRNAs based on SaCas9 (ga) and four sgRNAs based
on SpCas9 (g) were designed within the erythroid enhancer of the BCL11A gene.
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(chronic myelogenous leukemia, CML) and KG-1 as a human hematopoietic progenitor cell line model
were cultured in RPMI 1640 medium (high glucose) (Sigma) supplemented with 2.0 mM L-glutamine
(Life Technologies Gibco), 1% penicillin/streptomycin (Pen-Strep; Life Technologies Gibco,
#15140e122), and 20% FBS for KU812, and 10% FBS for KG-1 cell lines. Transfection of HEK293T cells
with pMLM3636 and hCas9 plasmids for CRISPR/SpCas9 system, as well as VVT1 and BPK2139 for
CRISPR/SaCas9 system were performed using Lonza Nucleofector® Kit V (program CM-130), as pre-
viously described [1].
KU812 and KG-1 cell lines were transfected with pMAK-gA þ gC, pMAK-gA þ gD, pMAK-gB þ gC,
and pMAK-gB þ gD vectors using the Neon® Transfection System 100 ml Kit (Thermo Fisher Scientiﬁc),
as previously described [1].
2.3. Cleavage activity of sgRNAs in cultured cells
CRISPR-Cas9 editing efﬁciency with the different sgRNAs was assessed by T7 Endonuclease assay
(New England Biolabs). Forty-eight hours after transfection, genomic DNA (gDNA) was extracted using
the E.Z.N.A.® Tissue DNA Kit (Omega Bio-tek), and 50 ng of the gDNA was ampliﬁed by target PCR
primer pairs ﬂanking the sgRNA-targeted region with Phusion® High-Fidelity DNA Polymerase (New
England Biolabs), based on the manufacturer's instructions. Following ampliﬁcation, PCR amplicons
were melted, annealed (5 min at 95 C, 95 Ce25 C at 0.5 C/30 sec, and 15 min at 4 C), and were
treated by T7EI enzyme (New England Biolabs) for 20 min at 37 C and run on a 2% agarose gel. To
assess the gene modiﬁcation efﬁciency, DNA band intensities were quantiﬁed using ImageJ software
(http://imagej.nih.gov/ij/) using the following formula, as previously described:
% gene modiﬁcation ¼ 100  (1 e (1- fraction cleaved)1/2) [13].
2.4. Generation of genomic deletions using the CRISPR-Cas9 system
Forty-eight hours post electroporation, transfected cells were plated at limiting dilution with
30 cells per 96-well plate to ﬁnd homozygously deleted clones. After either 14 or 21 days of clonal
expansion, genomic DNA was extracted from bulk cells as well as edited clones using DNA lysis buffer
(Direct PCReTail PEQGOLD, USA). Single-cell clones were screened for monoallelic deletion via PCR to
amplify the targeted sequence using a primer set ﬂanking the two sgRNA; one primer for upstream of
Fig. 3. Evaluation of SaCas9 cutting efﬁciency in HEK293Tcells. The mutation frequency of sgRNAs was evaluated using T7
endonuclease I assay (A), and Sanger sequencing (B) in HEK293T cells transfected with the VVT1-aI, VVT1-aII, and BPK2139, a human
expression vector for S.aureus Cas9, was a gift from Keith Joung (Addgene plasmid # 65776) [8]. The expected band sizes of gRNA-gI
and gRNA-gII after digestion with T7 enzyme were 177 bp, 181 bp, and 226 bp, 127 bp, respectively. However, no difference was
observed before and after digestion by T7 enzyme.
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sgRNA-A and sgRNA-B, and another primer for downstream of sgRNA-C and sgRNA-D to amplify across
the deletion sequence. Biallelic deleted clones were identiﬁed via the absence of non-deleted PCR
band, and presence of deleted PCR band.
2.5. Measurement of BCL11A and g -globin gene expression in modiﬁed cells
Total RNAs were isolated from the bulk cells as well as edited colonies using RNeasy Mini Kit
(Qiagen) and were DNase-treated with Ambion® TURBO DNA-free™ DNase (Invitrogen™), according
to the manufacturer's instructions. One microgram of extracted RNA was used for the generation of
cDNA using the iScript™ cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's speciﬁcations.
Levels of BCL11A, g -globin, and GAPDH as an internal control were quantiﬁed by qPCR using the
following primers: BCL11A primer (fw): 50-TTGCCCCAAACAGGAACACA-30, BCL11A primer (rv): 50-
CGGGGCATATTCTGCACTCA-30, HbF primer (fw): 50-CTTCAAGCTCCTGGGAAATGT-30, g -globin primer
(rv): 50-GTCACCATCTTCTGCCAGGA-30, GAPDH primer (fw): 50-TCCACCACCCTGTTGCTGTAG-30, GAPDH
Fig. 4. Targeted deletion of the BCL11A enhancer with CRISPR-Cas9. Targeted deletion of the core sequence of the þ58DHS within
the erythroid-speciﬁc enhancer of the BCL11A gene using the combination of sgRNAs AC, AD, BC, and BD was conﬁrmed by con-
ventional PCR. PCR was performed (A) on the bulk of the KU812 cells, and (B) on the bulk of the KG-1 cells. (C) Homozygously
deleted (Biallelic deletion) clones of KU812 cells, and (D) KG-1 cells. Expected band sizes for gA þ gC were as ND: 920 bp, and D: 556
bp; for gA þ gD were as ND: 1194 bp, and D: 658 bp; for gB þ gC were as ND: 775 bp, and D: 537 bp; for gB þ gD were as ND: 1049
bp, and D: 639 bp. Abbreviations: D: deleted band. ND: Non-deleted band. NC: negative control. BenchTop 100 bp DNA Ladder,
Promega, Cat.: #G8291 was used as the marker. All experiments were performed twice.
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Fig. 5. qRT-PCR Analysis of BCL11A and g-globin gene expression. Real-time PCR was performed on mRNA puriﬁed from bulk cells
and edited clones to assess BCL11A and g-globin mRNA levels. The qRT-PCR was normalized to the level of human GAPDH in cells
treated with four different pairs of sgRNA in two independent experiments. Evaluation of BCL11A (A. I), and g-globin (A. II)
expression in bulk and edited clones of KU812 cells treated by all combination of sgRNAs. Clone #2 from the combination of sgRNAs
A and C, and clone #5 from transfection of sgRNAs A and D, indicated signiﬁcant differences (p-value < 0.0001). Unpredictably, these
clones showed a signiﬁcant reduction in g-globin expression despite the deletion. Evaluation of BCL11A expression in bulk and
edited clones of KG-1 cells treated by all combination of sgRNAs (B.I), statistically, a signiﬁcant difference was found compared with
untreated control (B.II). Results from RT-qPCR have been depicted as relative fold change, which was calculated using the ddCT
method [9,10], in which fold change data have been represented as 2ddCT. Data were analyzed with GraphPad Prism software v6.0
and expressed as mean ± S.E.M. Statistically signiﬁcant differences were identiﬁed by Student t-test compared to untreated cells and
were indicated as follows: ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
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primer (rv): 50-ACACCCACTCCTCCACCTTTG-30. Quantitative RT-PCR was performed in duplicate or
triplicate using the QuantStudio™ 7 Flex Real-Time PCR Systems (Applied Biosystems) with SsoFast
EvaGreen Supermix (Bio-Rad) or StepOne Plus Real-Time PCR Systems (Applied Biosystems) with the
RealQ Plus 2 Master Mix Green High ROX™ (Ampliqon) following the manufacturer's procedures.
SsoFast EvaGreen Supermix PCR conditions were as follows: 5 min at 98 C, 40 cycles of 10 s at 98 C
and 20 s at 60 C. RealQ Plus 2 Master Mix Green PCR conditions were as the following: 15 min at
95 C, 40 cycles of 20 s at 95 C, 30 s at 60 C, and 30 s at 72 C. The relative values of the transcripts
were normalized to that of GAPDH gene and analyzed using the 2-ddCT method. A standard curve for
each genewas made from serial dilutions of the cDNA. Duplicate negative controls (no template cDNA)
were also run with every experimental plate to assess the speciﬁcity, and to rule out contamination.
2.6. Statistical analysis
Results from RT-qPCR were depicted as relative fold change, which was calculated using the ddCT
method, in which fold change data represented as 2-ddCT. Statistical analysis was performed using 2-
tailed student t-test (Prism software v6.0, GraphPad Software).
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